牛源金黄色葡萄球菌与无乳链球菌荚膜多糖蛋白结合疫苗的研制与免疫原性研究OA北大核心CSTPCD

To evaluate the immunogenicity of vaccines made from capsular polysaccharide-protein conjugate from bovine Streptococcus agalactiae A20 strain and Staphylococcus aureus J581 strain,three batches of capsular polysaccharides were tested for polysaccharides,proteins,and nucleic acids.In addition,purified capsular polysaccharides of S.aureus J581 strain and S.agalactiae A20 strain were combined with tetanus toxoid to prepare six types of conjugate vaccines with polysaccharide-protein concentrations of 5 μg/mL,10 μg/mL,and 15 μg/mL,as well as a mixture vaccine with polysaccharide-protein mass concentrations of 10 μg/mL from J581 and A20 capsules.In the end,mice were immunized separately with these varying vaccine types.The indirect ELISA method and IgG antibody kit were used to determine specific antibody levels and antibody titers against J581 and A20 capsular polysaccharides in mouse serum at different time periods before and after vaccination.Among the three batches of purified capsular polysaccharides prepared,the average mass concentration of J581 polysaccharide was 49.78 mg/L,and the average mass concentration of A20 polysaccharide was 55.76 g/L.These two polysaccharides contained less than 1％protein and nucleic acid,which was consistent with vaccine production requirements.The results of the mouse immune experiment showed that six types of capsular polysaccharide-protein conjugate vaccines and capsular polysaccharide mixed vaccines with different polysaccharide contents can stimulate the body to produce a certain level of specific antibody titers and IgG antibodies,which reach a specific level on the 28th day.J581 and A20 antibody titers and specific IgG levels were significantly higher in the mixed vaccine group than those in the 6 single vaccine groups(P＜0.05).The study lays the foundation for developing vaccines against S.aureus and S.agalactiae containing capsular polysaccharide-protein conjugates.